Effects of switching to everolimus versus continuing a calcineurin inhibitor on biomarkers of fibrosis, tubular injury, inflammation and glomerular injury in renal transplant recipients
Latest Information Update: 19 May 2013
At a glance
- Drugs Everolimus (Primary) ; Calcineurin inhibitors
- Indications Renal transplant rejection
- Focus Biomarker; Pharmacodynamics
- 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 19 May 2013 New trial record